Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AC Immune SA ACIU

Healthcare Biotechnology
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small... see more

Recent & Breaking News (NDAQ:ACIU)

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

GlobeNewswire November 3, 2023

AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer's Disease as a Surrogate of Clinical Efficacy on November 9, 2023

GlobeNewswire November 2, 2023

AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic

GlobeNewswire October 27, 2023

AC Immune Announces Upcoming Presentations at the 16th CTAD Conference

GlobeNewswire October 17, 2023

AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023

GlobeNewswire October 5, 2023

AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023

GlobeNewswire September 5, 2023

AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

GlobeNewswire August 4, 2023

AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023

GlobeNewswire July 28, 2023

AC Immune SA Appoints New Chief Medical Officer

GlobeNewswire July 26, 2023

AC Immune Showcasing Precision Medicine Programs at AAIC 2023

GlobeNewswire July 3, 2023

AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer's Disease

GlobeNewswire June 27, 2023

AC Immune Holds Annual General Meeting of Shareholders

GlobeNewswire June 23, 2023

AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update

GlobeNewswire April 28, 2023

AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer's Disease

GlobeNewswire April 5, 2023

AC Immune at AD/PD(TM) 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline

GlobeNewswire March 20, 2023

AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update

GlobeNewswire March 16, 2023

AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023

GlobeNewswire March 8, 2023

AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43

GlobeNewswire February 7, 2023

AC Immune to Present at the SVB Securities Global Biopharma Conference

GlobeNewswire February 2, 2023

AC Immune's ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer's Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

GlobeNewswire January 26, 2023